Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 10/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8778596 | 0.89 | HPGD (0.47) | HTTSMN1; SMN2MEN1ALDH1A1PPP1CA | |
| SCHEMBL3786284 | 0.88 | GRM5 (0.52) | HTTSMN1; SMN2MEN1PPP1CAKMT2A | |
| SCHEMBL8778654 | 0.87 | SMN1; SMN2 (0.52) | HTTSMN1; SMN2ALDH1A1PPP1CAL3MBTL1 | |
| SCHEMBL8775116 | 0.79 | CYP1A2 (0.47) | SMN1; SMN2MEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL8778658 | 0.78 | CYP1A2 (0.40) | HTTSMN1; SMN2MEN1ALDH1A1PPP1CA | |
| SCHEMBL8778663 | 0.77 | ABCG2 (0.49) | HTTSMN1; SMN2MEN1ALDH1A1PPP1CA | |
| SCHEMBL8778643 | 0.76 | ALDH1A1 (0.44) | SMN1; SMN2MEN1ALDH1A1PPP1CAKMT2A | |
| SCHEMBL8777762 | 0.74 | USP1 (0.39) | HTTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL8777404 | 0.74 | KMT2A (0.52) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL8515839 | 0.73 | CYP1A2 (0.40) | SMN1; SMN2MEN1ALDH1A1KMT2AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012069652-A2 | FUNGICIDE MIXTURES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010136475-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129875-A1 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES | NAT1, NQO2, NOX1 | HTT 2814/4885SMN1; SMN2 3646/4885MEN1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.